News

November 9, 2011 – AstraZeneca announced that a combined expert committee of American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and Society for Cardiovascular...

November 9, 2011 — Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved Xarelto to reduce the risk of stroke and systemic embolism in patients with...

October 24, 2011 – The American College of Cardiology (ACC) announced it is expanding its outpatient PINNACLE Registry with a new platform focusing on atrial fibrillation (AF), including the next...

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular...

September 8, 2011 – A randomized multicenter, open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months'...

September 6, 2011 — The European Society of Cardiology (ESC) released the latest version of its guidelines for managing patients presenting without persistent ST-segment elevation. This version...

August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated with 26 percent relative risk reduction in cardiovascular death, myocardial...

July 21, 2011 – The U.S. Food and Drug Administration (FDA) today approved AstraZeneca’s blood-thinning drug ticagrelor (Brilinta) to reduce cardiovascular death and heart attack in patients with...

April 7, 2011 – Primary results from the RADAR Phase 2b clinical trial were announced at the American College of Cardiology (ACC) 2011 60th Annual Scientific Session. The trial looked at Regado...

April 7, 2011 – New study results have evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on clopidogrel (Plavix). The results showed that in healthy subjects,...

April 1, 2011 – Oral antiplatelet therapy Effient (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing...

April 1, 2011 –Results from the RADAR Phase 2b clinical trial will be announced at the i2 Summit during the American College of Cardiology (ACC) 2011 Annual Scientific Session and Expo. The trial...

March 25, 2011 – The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a focused update to the 2007 guidelines for the managing patients with unstable...

March 10, 2011 – New guidelines have been published in The Annals of Thoracic Surgery that include point-of-care testing for platelet reactivity as a new recommendation for...

March 1, 2011 – A new study assessing the utility of genetic testing to determine a personalized warfarin dose for individual patients has begun at Overlake Hospital Medical Center in Bellevue,...

February 24, 2011 – Upsher-Smith Laboratories, is voluntarily recalling one lot (lot #284081) of Jantoven Warfarin Sodium, USP, 3 mg tablets, an anticoagulant with an expiration date of September...

February 16, 2011 – The newly approved drug dabigatran is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation, according to updated guidelines...

February 10, 2011 – A Phase 2 clinical trial has been initiated to test the safety and efficacy of drug to reverse heparin in patients undergoing percutaneous coronary intervention (PCI). The...

December 29, 2010 - Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific...